Anti-baff nanobody and preparation and application thereof
By preparing and humanizing camel-derived chimeric anti-BAFF nanobodies, the shortcomings of existing BAFF monoclonal antibodies in the treatment of autoimmune diseases have been overcome. This has achieved effective blocking of the BAFF signaling pathway and disease inhibition, demonstrating excellent stability and therapeutic potential.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- SHENYANG SUNSHINE PHARMA CO LTD
- Filing Date
- 2025-01-15
- Publication Date
- 2026-07-17
AI Technical Summary
Existing BAFF monoclonal antibody drugs, such as Belimumab, still have unmet clinical needs in the treatment of autoimmune diseases such as systemic lupus erythematosus. There is a need to develop better anti-BAFF nanobodies to more effectively block the BAFF signaling pathway and inhibit its biological activity.
Camel-derived antibodies targeting BAFF were obtained by panning antibody libraries of immunized camels and phage display. Camel-derived chimeric anti-BAFF nanobodies were prepared by combining the Fc domain of IgG1 and then humanized to obtain humanized anti-BAFF nanobodies with better expression levels and biological activity.
It effectively blocks the BAFF signaling pathway, significantly inhibits BAFF-induced B cell activation and proliferation, and is superior to the existing drug Belimumab. It has excellent stability and clinical potential and is suitable for the treatment of a variety of autoimmune diseases.
Smart Images
Figure BDA0005244247070000101 
Figure BDA0005244247070000111 
Figure BDA0005244247070000121